The Founders of New Day Pharmaceuticals are offering a unique investment opportunity in our mission to bring innovative, naturally derived therapies to market.
We are currently conducting an equity offering to raise $7.5 million at a $10 million pre-money valuation—available exclusively to accredited investors.
Exclusive Early Investor Incentive
Special Offer: For the first $100,000 of investment, we are offering a pre-money valuation of $3,000,000, representing a 70% discount off the full round valuation.
Be part of New Day Pharmaceuticals’ mission to revolutionize natural healthcare solutions and bring life-changing therapies to market.
Limited-Time Offer: The first $100,000 of investment qualifies for a 70% discount at a pre-money valuation of $3 million.
Don’t miss out—secure your spot today!
Click below to learn more and connect with our investment team.
Investing in early-stage companies involves significant risk, including the potential loss of your entire investment. These securities are being offered under Regulation D, Rule 506(c) and are only available to accredited investors as defined by the Securities and Exchange Commission (SEC).
By investing, you acknowledge that you understand and accept these risks and that you are financially capable of bearing a total loss of your investment. This offering has not been registered with, or approved by, the SEC or any other regulatory authority.
This is not an offer to sell securities or a solicitation of an offer to buy, which can only be made through official offering documents. Potential investors should conduct their own due diligence and consult with a financial advisor or legal professional before making any investment decision.